. Newborn rat response to single versus combined cGMP-dependent pulmonary vasodilators. Am J Physiol Lung Cell Mol Physiol 306: L207-L215, 2014. First published November 15, 2013 doi:10.1152/ajplung.00164.2013.-Inhaled nitric oxide (NO) and other cGMP-or cAMP-dependent pulmonary vasodilators are often used in combination for the treatment of the persistent pulmonary hypertension of the newborn syndrome. There is in vitro evidence to indicate that NO downregulate the pulmonary vascular response to cGMP-dependent agonists raising concern as to whether a synergistic effect is observed when employing a combined strategy in newborns. Hypothesizing that a synergistic effect is absent, we evaluated newborn and juvenile rat pulmonary arteries to determine the individual and combined vasodilatory effect of cGMP-and cAMP-dependent agonists. In precontracted near-resistance pulmonary arteries, the addition of sildenafil reduced vasorelaxation response to NO donor S-nitroso-N-acetyl penicillamine (SNAP). A similar decrease in SNAP-induced vasodilation was observed in arteries pretreated with BAY 41-2272 (10 Ϫ9 M), a soluble guanylate cyclase stimulator cGMP, and its downstream protein kinase activator. cGMP also reduced the vasorelaxant response to the cAMPdependent forskolin. Inhibition of endogenous vascular NO generation enhanced SNAP-induced relaxation. The present data suggest that the mechanism involved in the cGMP desensitization to other relaxant agonists involves downregulation of the small heat shock protein HSP20 and is evident in rat pulmonary and systemic vascular smooth muscle cells. In newborn rats with chronic hypoxia-induced pulmonary hypertension, the combination of sildenafil and inhaled NO resulted in a lesser reduction in pulmonary vascular resistance compared with their individual effect. These data suggest that clinical exposure to one cGMP-dependent pulmonary vasodilator may affect the response to other cGMP-or cAMP-mediated agonists.
THE SUCCESSFUL TRANSITION from fetal to postnatal life depends on a rapid decrease in pulmonary vascular resistance (PVR) at birth. The factors accounting for this dramatic reduction in PVR are incompletely understood, but nitric oxide (NO) is known to play an important role. The maintenance or recurrence of a high PVR postnatally characterizes the persistent pulmonary hypertension of the newborn syndrome (PPHN), a life-threatening condition requiring early and aggressive therapeutic interventions to improve and maintain adequate blood oxygenation (21) .
Inhaled NO is the standard of care to therapeutically promote pulmonary vasodilation in infants with PPHN, and significant clinical improvement is observed in many infants subjected to this therapy (2, 4) . Yet, when response to inhaled NO is absent or partial, the clinical use of alternative agents with pulmonary vasodilatory properties may be contemplated (29) .
NO is endogenously generated by nitric oxide synthases (NOS) via the conversion of L-arginine into L-citrulline that in turn promotes cGMP generation via soluble guanylyl cyclase (sGC) activation. Pulmonary vasodilation is the result of cGMP-mediated activation of the cGMP-dependent protein kinase (PKG) and ultimately dephosphorylation of myosin by the myosin light chain phosphatase (5, 6) . cGMP is converted into inactive GMP by several phosphodiesterases of which phosphodiesterase-5 (PDE5) is the most important isotype in the lung. PDE5 inhibitors are therapeutically employed to promote pulmonary vasodilation, and sildenafil is the most commonly used in neonates (26) . cAMP exerts its effects via an alternate pathway. Agonists such as prostacyclin promote pulmonary vasodilation via stimulation of cAMP-dependent protein kinase (PKA) (30) . Type 3 phosphodiesterases (PDE3) break down cAMP, and pharmacological inhibitors of this enzyme such as milrinone are commonly used in neonates to induce pulmonary vasorelaxation.
PKG and PKA signaling pathways converge on common downstream effectors of myosin light chain phosphatase stimulation to promote vasodilation. Clinically, this pathway's commonality has been explored therapeutically by associating inhaled NO and cGMP-and cAMP-dependent agonists to obtain an additive pulmonary vasodilatory effect.
Animal studies have shown that sildenafil enhances the inhaled NO effect on pulmonary vasorelaxation (16, 27) . This contrasts with in vitro evidence that chronic exposure to NO downregulates the vasorelaxation response to an NO donor (17) . Perkins et al. have shown that prolonged treatment of porcine pulmonary arteries with NO donor decreased cGMP sensitivity and PKG activity, leading to reduction of NOdependent vasodilation (20) .
Given that this issue has not been explored in newborns, our goal was to conduct in vitro and in vivo studies to evaluate the newborn rat pulmonary vascular response to single and combined cGMP-and cAMP-dependent agonist exposure. We hypothesized that the magnitude of the pulmonary vasorelax-ation response to NO is reduced in the presence of cGMPdependent agonists because of vascular desensitization.
MATERIALS AND METHODS

Chemicals and Reagents
All chemicals and reagents were obtained from Sigma Aldrich (Oakville, Ontario, Canada), unless otherwise indicated.
Animals
All procedures were conducted according to criteria established by the Canadian Council on Animal Care and were approved by the Animal Care Committee of The Hospital for Sick Children Research Institutes.
Organ Bath Studies
Sprague Dawley rats were studied between 2 and 5 days (newborn) and 14 and 21 days of life (juvenile). The animals were killed with an overdose of pentobarbital sodium (50 mg/kg ip; BHD, Toronto, ON, Canada), the lungs were quickly removed en bloc, and third-generation intrapulmonary arteries were obtained while the lungs were maintained in ice-cold bubbled Krebs-Henseleit solution (in mM: 115 NaCl, 25 NaHCO3, 1.38 NaHPO4, 2.51 KCl, 2.46 MgSO4·7H2O, 1.91 CaCl2, and 5.56 dextrose).
The functional evaluation of newborn pulmonary arteries has been previously described (1, 18) . Briefly, third-generation lung intralobar pulmonary artery ring segments (average diameter 80 -100 m and length ϭ 2 mm) were dissected free and mounted in a wire myograph (Danish Myo Technology). Isometric changes were digitized and recorded online (Myodaq; Danish Myo Technology, Aarhus, Denmark). Tissues were bathed in Krebs-Henseleit buffer bubbled with air-6% CO 2 and maintained at 37°C. After 1 h of equilibration, the optimal tissue resting tension was determined by repeated stimulation with 128 mM KCl until maximum active tension was reached. All subsequent force measurements were obtained at optimal resting tension.
The vessels were preincubated for 30 min in the presence or absence of sildenafil (10 Ϫ8 M), cGMP (10 Ϫ4 M), Sp-8-Br-PETcGMPS (10 Ϫ5 M; BIOLOG Life Science Institute, Bremen, Germany), Y-27632 (10 Ϫ7 M; WelFide, Osaka, Japan), asymmetric dimethylarginine (ADMA; 10 Ϫ4 M), or sGC stimulators BAY 41-2272 (10 Ϫ6 or 10 Ϫ9 M) and BAY 63-2521 (6 ϫ 10 Ϫ9 ; MedChem Express, Princeton, NJ). The thromboxane A2 mimetic U-46619 (Cayman Chemical, Ann Arbor, MI) at the effective concentration to induce 75% of maximal contraction or KCl (66 mM) was used to induce muscle contraction. The pulmonary vascular muscle relaxation dose response was obtained with SNAP, forskolin, or cGMP and expressed as a percentage of the maximum contraction.
Chronic Hypoxia-Induced Rat Model of Neonatal Pulmonary Hypertension
A previously described newborn rat model of chronic hypoxiainduced pulmonary hypertension was used (1, 7, 14, 18) . Briefly, shortly after birth, newborn rats were continually exposed to 13% oxygen for 14 days in a computer-controlled environmental chamber (Oxycycler), as previously described (1) .
The in vivo PVR changes observed following exposure to inhaled NO (20 parts/million) alone, or in combination with sildenafil (100 mg/kg ip) (10) on the chronic hypoxia-treated animals, were comparatively measured. For that, the animals were anesthetized with intraperitoneal 40 mg/kg ketamine and 6 mg/kg xylazine and maintained warm by placing them on a heating pad. Their body temperature was monitored with a rectally placed telethermometer. Following basal echocardiographic measurements, the pups were randomly assigned to receive either sildenafil or saline (similar volume as sildenafil) intraperitoneally.
Echocardiographic measurements were repeated 20 min after saline or sildenafil treatment. Finally, the animals were exposed to inhaled NO combined with oxygen to provide an FI O2 ϭ 0.21, as previously described (14) , and, after a 20-min period, the echocardiographic measurements were repeated. Nine animals were allocated to each of the in vivo treatment groups (inhaled NO alone or in combination with sildenafil). This sample size allows for detection of a 25% change in the estimated PVR with a power of 90% and two-tailed significance level (alpha) of 0.05.
Echocardiography and PVR
PVR was evaluated by two-dimensional echocardiography/Doppler ultrasound as previously described (14, 18) . Briefly, a short-axis view at the level of the aortic valve was obtained, and the pulmonary artery was identified using color flow Doppler. The pulmonary arterial acceleration time (PAAT) was measured as the time from the onset of systolic flow to peak pulmonary outflow velocity and the right ventricular ejection time (RVET) as the time from onset to completion of systolic pulmonary flow. The inverse ratio of PAAT to RVET was used as a surrogate for PVR.
Primary Vascular Smooth Muscle Cells
Primary smooth muscle cells (SMC) were isolated and cultured using previously reported and well-established methodologies (18, 25) . Briefly, aortas and pulmonary arteries were dissected in ice-cold DMEM (Life Technologies), split open, minced, and washed with ice-cold PBS supplemented with 1% penicillin/streptomycin/fungizone solution (Wisent, Montreal, Quebec, Canada). Tissues were then incubated in 0.25% Trypsin/EDTA solution (Life Wisent). After 15 min the solution was replaced by DMEM supplemented with 10% FBS (Wisent) and 2.5% penicillin/streptomycin/fungizone solution and incubated at 37°C, 5% CO 2 with 90% humidity followed by media changes at 24 h and every 4 days until confluence. SMC phenotype was confirmed by Western blot analysis using anti-smooth muscle actin antibody (Thermo Fisher Scientific, Ottawa, Ontario, Canada). Lack of endothelial cell contamination was confirmed by Western blot analysis using anti-CD31 antibody (Santa Cruz Biotechnology, Santa Cruz, CA). As a positive control, rat aorta endothelial cells isolated by collagenase type II (1 mg/ml) tissue digestion and subsequent pull down with magnetic beads (New England Biolabs, Ipswich, MA) coated with biotinylated rat anti-mouse CD31 antibody (BD PharMingen, San Diego, CA) were used.
We further confirmed the phenotype of the cultured cells as smooth muscle as follows. Cells were grown on a cover slip and stained with smooth muscle actin (1:200 dilution; NeoMarkers, Fremont, CA) and secondary goat anti-mouse IgG Cy3 (dilution 1:50; Abcam, Cambridge, UK) antibodies. The cells were visualized by fluorescent microscopy using Vectashield mounting medium with DAPI (Vector Laboratories, Burlingame, CA).
Western Blotting for Phospho-Vasodilator-Stimulated Phosphoprotein, Phospho-Heat Shock Protein 20, and PhosphoHeat Shock Protein 27
Third-generation intrapulmonary arteries and primary pulmonary arterial SMC were preincubated with cGMP (10 Ϫ4 M) or KrebsHenseleit buffer for 30 min, treated with SNAP (10 Ϫ4 M) for 1 h, and quickly frozen in liquid nitrogen for subsequent analysis. Primary SMC maintained in serum-free media for 1 h were pretreated with cGMP (10 Ϫ4 M) or Krebs-Henseleit buffer for 30 min followed by SNAP (10 Ϫ4 M) for 1 h. Cells and frozen intrapulmonary arteries were lysed in 10 mM Tris·HCl, pH 7.4, lysis buffer containing 1% Triton X-100 and protease/phosphatase inhibitor cocktails (Thermo Fisher Scientific, Rockford, IL) and centrifuged at 14,000 rpm for 30 min. Protein concentration was determined by Bradford assay.
Equivalent amounts of lysate proteins in Laemmli buffer were fractionated on SDS-PAGE, transferred to polyvinylidene difluoride membranes, and blotted. Membranes were blocked with 5% skim milk for anti-␣-tubulin antibody, or 5% BSA. The following primary antibodies were used at 4°C overnight: phospho (p)-vasodilatorstimulated phosphoprotein (VASP; Ser 239 ; Cell Signaling Technology, Danvers, MA), 1:1,000; p-heat-shock protein (HSP) 20 (Ser 16 ; Abcam), 1:500; p-HSP27 (Abcam), 1:1,000; and ␣-tubulin (Abcam), 1:10,000. Appropriate IgG conjugated with HRP were used as secondary antibodies. The enhanced chemiluminescence (Perkin Elmer, Shelton, CT) reagent was used for detection. Band intensities were quantified by ImageJ software (NIH, Bethesda, MA).
Data Analysis
Data were evaluated by one-or two-way ANOVA for repeated measures with multiple comparisons obtained by the Tukey-Kramer test, or unpaired Student's t-test, when appropriate. Statistical significance was determined at P Ͻ 0.05. All statistical analyses were performed with the Number Cruncher Statistical System software (NCSS, Kaysville, UT). Data are presented as means Ϯ SE.
RESULTS
In Vitro Studies
NO donor-mediated vasorelaxation is reduced by sildenafil and enhanced by ADMA. Precontracted newborn rat pulmonary arteries responded to the NO donor SNAP with dosedependent vasorelaxation. The magnitude of SNAP-induced relaxation was significantly (P Ͻ 0.01) reduced following vessel preincubation with sildenafil (10 Ϫ8 M) and potentiated by the endogenous NOS inhibitor ADMA (10 Ϫ4 M) (Fig. 1A) . Preincubation with the sGC stimulator BAY 41-2272 resulted in a concentration-dependent effect on the SNAP-induced vasorelaxation (Fig. 1B ). At the highest tested concentration (10 Ϫ6 M) BAY 41-2272 enhanced, whereas at 10 Ϫ9 M it significantly reduced, the SNAP-induced vasorelaxation (P Ͻ 0.01).
We proceeded to investigate whether the desensitization of the SNAP response was unique to neonatal arteries. As shown in Fig. 2 , preincubation with cGMP significantly (P Ͻ 0.01) reduced the SNAP-induced vasorelaxation in pulmonary arteries derived from both newborn ( Fig. 2A) and juvenile (Fig. 2B) animals.
Mechanism accounting for the cGMP-induced desensitization to NO stimulation. To further evaluate the mechanism accounting for the sildenafil-induced downregulation of SNAP-mediated vasorelaxation, pulmonary arteries were preincubated with Sp-8-Br-PET-cGMPs, a PKG stimulator. A trend was noted in pulmonary arteries derived from 2-to 5-day-old pups, but Sp-8-Br-PET-cGMPs significantly (P Ͻ 0.01) reduced the magnitude of the SNAP-induced pulmonary arterial relaxation in juvenile vessels (Fig. 2) . Together these data suggest that the cGMP-reducing effect on the NO-dependent relaxation results from desensitization of this pathway downstream from PKG.
Next, we asked whether the desensitization by excess cGMP could interfere with the cAMP-dependent pulmonary arterial vasorelaxation since both PKG and PKA activate myosin light chain phosphatase via a common pathway. Preincubation with cGMP (10 Ϫ4 M; Fig. 3A ), or the sGC stimulator BAY 63-2521 (6 ϫ 10 Ϫ9 M; Riociguat; Fig. 3B ), significantly (P Ͻ 0.01) decreased the forskolin-induced pulmonary vasorelaxation, further suggesting that these downregulated responses are downstream of PKG and PKA activation. Incubation with higher than tested concentrations of BAY 63-2521 was not feasible since the Ͻ5-day-old pup pulmonary arteries failed to subsequently contract even when stimulated with U-46619 at concentrations as high as 10 Ϫ5 M. The potential involvement of Rho kinase activation on the downregulation of the SNAP-dependent vasorelaxation was studied. To evaluate involvement of Rho kinase, we tested whether Y-27632 (10 Ϫ7 M) would prevent the reduced SNAPdependent dose response following incubation with cGMP in newborn pulmonary arteries precontracted with U-46619. In the presence of Y-27632, preincubation with cGMP reduced the magnitude of the SNAP-dependent dose response (P Ͻ 0.01), suggesting that this phenomenon is not mediated via the Rho kinase pathway (Fig. 4A) .
Because potassium channel activation has been reported to interact with the PKG-induced relaxation signaling pathway (22), we evaluated their potential involvement in the partial suppression of the SNAP-induced vasorelaxation by cGMP. We reasoned that precontraction of pulmonary arterial muscle with KCl (66 mM) would abolish the suppressive effect of cGMP incubation on the SNAP-dependent relaxation, if mediated via potassium channels. As shown in Fig. 4B , preincubation with cGMP significantly reduced the magnitude of the SNAP-induced vasorelaxation response in KCl-precontracted vessels, suggesting that potassium channels are not involved in this phenomenon.
Once activated by NO/cGMP, PKG phosphorylates a number of SMC proteins that ultimately act on myosin light chain phosphatase to promote pulmonary vasodilation. These include VASP and HSP20 and HSP27; the latter two have been shown to be downstream targets of PKG and PKA (13, 32, 33) . Hypothesizing that the reduced SNAP-dependent newborn rat pulmonary vasorelaxation was related to desensitization at the HSP20 protein, we evaluated its phosphorylation in response to SNAP alone or in combination with cGMP. Experiments were conducted in third-to fourth-generation newborn pulmonary arteries similar to the ones mounted on the wire myograph.
Pulmonary arteries from rats incubated with SNAP showed a significant increase in p-VASP content (P Ͻ 0.01) compared with basal levels, which was not further enhanced by the addition of cGMP (Fig. 5A ). Yet, whereas HSP20 phosphorylation was increased following SNAP exposure (P Ͻ 0.01), the combination of SNAP ϩ cGMP resulted in p-HSP20 content similar to unstimulated control levels (Fig. 5B) .
Compared with HSP20, phosphorylation of HSP27 has been shown to exhibit an inversely proportional response such that smooth muscle relaxation is ultimately modulated by the phosphorylation state of both small heat shock proteins (13) . Therefore, we measured the p-HSP27 content of pulmonary arterial tissue and primary SMC obtained from these vessels in response to cGMP alone or in combination with SNAP. No significant changes in HSP27 phosphorylation were observed (Fig. 5C) .
Primary SMC derived from juvenile third-to fourth-generation pulmonary arteries and 2-to 5-day-old rat aorta were in vitro exposed to SNAP alone, or in combination with cGMP ( Fig. 6) . A significant increase in p-VASP content was documented for both sets of muscle cells following incubation with SNAP that was not distinct from the cGMP ϩ SNAP-exposed samples (Fig. 6, A and C) . Similar to the results obtained from pulmonary arterial tissue, SNAP exposure increased the muscle cell p-HSP20 content, but the combination of cGMP ϩ SNAP resulted in phosphorylation levels not statistically different from control samples (Fig. 6, B and D) .
Enhanced SNAP-induced relaxation in chronic hypoxiaexposed pulmonary arteries. We proceeded to evaluate whether the observed ex vivo effect of cGMP on the NO donor-induced pulmonary vasorelaxation in newborn rat pulmonary arteries is also present in similar vessels derived from a chronic hypoxia-induced newborn rat model of pulmonary hypertension.
As shown in Fig. 7 , pulmonary arteries from chronic hypoxiaexposed rats exhibited a reduced (P Ͻ 0.01) endotheliumdependent (Fig. 7A ), but enhanced (P Ͻ 0.01) endotheliumindependent, relaxation (Fig. 7B) . Based on the present study data, the potentiation of the SNAP-dependent pulmonary vasorelaxation is the result of a reduced endothelium-dependent NO generation in vessels obtained from chronic hypoxiaexposed animals, a phenomenon similar to the response observed in normal vessels following ADMA-induced NOS inhibition (Fig. 1A) .
In Vivo Studies
We further comparatively evaluated the pulmonary vasodilatory effect of sildenafil alone, or in combination with inhaled NO, in chronic hypoxia-exposed 14-day-old rats. Compared with basal measurements, the echocardiographic-derived PVR measurements (1/PAAT/RVET) were significantly reduced (P Ͻ 0.01) to a similar extent when the animals were treated with either inhaled NO or sildenafil (Fig. 8) . However, when inhaled NO was provided to sildenafil-treated animals, the estimated PVR increased and was no longer significantly different compared with presildenafil basal levels (Fig. 8B) .
DISCUSSION
We demonstrated that the newborn and juvenile rat pulmonary arterial muscle relaxant response to either a NO donor or cAMP-dependent agonist was downregulated following preexposure to cGMP in vitro. In contrast, inhibition of endogenous NO generation with ADMA significantly enhanced the SNAPinduced pulmonary vasorelaxation. When studied in vivo, the PVR individual response to inhaled NO or sildenafil was superior to the combination of the two agents in chronic hypoxia-exposed pulmonary hypertensive juvenile rats. The mechanism accounting for the cGMP desensitization of pulmonary vasorelaxation involves smooth muscle-dependent downregulation of HSP20 phosphorylation and is also evident in aorta-derived cells.
The rationale for the current study was based on the clinical approach used in the treatment of infants with PPHN syndrome. It is well known that pulmonary vasodilation can be achieved via stimulation of either the cGMP-or cAMP-dependent pathways. Inhaled NO is the most common therapeutic approach for infants with this syndrome. A failure to achieve significant clinical improvement with this modality often leads to the combined use of inhaled NO with phosphodiesterase inhibitors such as sildenafil or milrinone. The additive effect of distinct cGMP-dependent pulmonary vasodilators, or the combination of cGMP and cAMP agonists, is currently viewed as therapeutically advantageous (31) . Yet, there is reason to question this approach.
Mullershausen et al. have previously shown that preincubation of adult rat aorta with an NO donor for as little as 10 min desensitizes the NO/cGMP signaling pathway, leading to a reduced subsequent NO donor-induced vasorelaxation response (17) . In the lung, others have shown that chronic in vitro treatment of adult porcine pulmonary artery with an NO donor reduces the subsequent response to a single concentration of the same agonist. The phenomenon was ascribed to cGMP pathway desensitization possibly via downregulation of sGC-specific activity (19) .
In the present study, we obtained newborn rat pulmonary in vitro and in vivo evidence of cGMP-induced vasorelaxation desensitization to a NO donor. Furthermore, in pulmonary arteries derived from rats with chronic hypoxia-induced pulmonary hypertension, we observed enhancement of the SNAPinduced pulmonary vasorelaxation (Fig. 7B) . This phenomenon is likely related to the reduced potential for endotheliumdependent NO generation in these vessels, as evidenced in this study by the reduced ACH-induced relaxation compared with control animal arteries. The mechanism accounting for this phenomenon is not fully understood, but the evidence from the present study indicates that it involves a factor downstream from PKG and is unrelated to rho kinase activation.
It is known that PDE5 is phosphorylated by PKG (5, 36) , and thus the cGMP-induced downregulation of the SNAP pulmonary vasorelaxation response observed in the present study could potentially be related to this mechanism. Yet, our findings are not in keeping with this possibility since NO donor response downregulation was also observed in vessels pre- Fig. 8 . Inhaled nitric oxide and sildenafil effect on the chronic hypoxiaexposed rat pulmonary vascular resistance (PVR). The PVR was estimated by echocardiograph in 18 2-wk-old rats chronically exposed to hypoxia before (basal) and treated with either saline followed by inhaled nitric oxide [iNO 20 parts/million (ppm); N ϭ 9] or sildenafil (1 mg/kg ip) followed by iNO (20 ppm ; N ϭ 9). PAAT, pulmonary arterial acceleration time; RVET, right ventricular ejection time. **P Ͻ 0.01 vs. basal levels by 1-way ANOVA and Tukey-Kramer multiple-comparison testing. Fig. 7 . Chronic hypoxia-exposed rat pulmonary arterial response to endothelium-dependent and -independent relaxation. Pulmonary arterial response to acetylcholine (ACh; N ϭ 20 -24; A) and the nitric oxide donor SNAP (N ϭ 4 -6; B) in vessels derived from air-treated (control) and chronic hypoxiaexposed 2-wk-old rats. **P Ͻ 0.01 compared with control values by 2-way ANOVA and Tukey-Kramer multiple comparison. treated with the PDE5 inhibitor sildenafil. It has also been reported that PKG can promote sGC phosphorylation, resulting in decreased activity of this enzyme (37) . This mechanism is also unlikely to have played a role in the present observations since exposure to Sp-8-Br-PET-cGMP (PKG stimulator) downregulated the SNAP-induced vasorelaxant response.
The data obtained following preincubation with the sGC stimulator BAY 41-2272 suggest that the cGMP downregulation is concentration dependent. At 10 Ϫ9 M, a concentration sufficiently low to enhance basal cGMP generation (as judged by the 10% reduction in U-46619-induced force) and in keeping with published data (28), BAY 41-2272 decreased the NO-dependent relaxation. Preincubation with a higher bath concentration (10 Ϫ6 M) enhanced the SNAP-induced relaxation likely as a result of BAY 41-2272 potentiation of sGC activity similar to the results reported by others in rat tracheal muscle (34) . Because forskolin is a cAMP-dependent agonist, the reduced pulmonary vasorelaxation in the presence of BAY 63-2521 suggests that the increased vascular basal cGMP generation induced by this accounts for the altered response.
Pulmonary vasorelaxation induced via adenylate cyclase stimulation activates PKA. In the present study, we showed that cGMP downregulated the pulmonary vasorelaxation response to forskolin, a cAMP-dependent agonist. In addition, following exposure to the sGC stimulator BAY 63-252, a significant reduction in forskolin-induced pulmonary vasomotor relaxation was observed. This suggests that the cGMPdependent desensitization involves downstream factors shared by both protein kinases. PKA and PKG mediate pulmonary vasorelaxation via phosphorylation of the common downstream target HSP20 (13, 35) , making this a potential mechanism involved in the cGMP desensitizing process.
HSP20 was first identified in rat and human skeletal muscle (8) , but more recently has been shown to be involved in vasorelaxation (3) . Of relevance to the present study is the previous report of increased porcine coronary arteries HSP20 phosphorylation in response to sildenafil exposure (32) . We demonstrated that SNAP increased pulmonary arterial tissue HSP20 phosphorylation, and the combined exposure of this NO donor with cGMP resulted in decreased p-HSP20 to levels similar to control values (Fig. 5) .
Vascular tissue cellular stress induces reduced vasorelaxation reported to be associated with a concomitant rise in HSP27 and fall in HSP20 phosphorylation (9) . In the myocardium, a positive correlation between tissue cGMP content and the magnitude of HSP27 phosphorylation has been reported (11) . This led us to evaluate the HSP27 phosphorylation in pulmonary arterial tissue in response to SNAP in the absence and presence of cGMP. No significant changes in HSP27 phosphorylation were documented in this study, suggesting that this factor is not involved in the cGMP-induced desensitization process.
Last, we investigated whether Rho kinase and calciumactivated potassium channels are involved in the pulmonary vasorelaxation desensitization by cGMP. The failure to show that such phenomenon was affected by the presence of a Rho kinase inhibitor and its occurrence following KCl-induced muscle contraction make the involvement of these factors in the desensitization process unlikely.
Interestingly, we also found that the cGMP-dependent pulmonary vasorelaxation desensitization is evident in response to NOS-dependent endogenous NO generation. We showed here that the NOS inhibitor ADMA potentiated the newborn pulmonary arterial vasorelaxation response to SNAP. Similar results have been reported by others in rat mesenteric arteries, rabbit hepatic arteries (23) , and rat aorta (15) . A similar phenomenon was also documented in the present study in pulmonary arteries derived from chronic hypoxia-induced hypertension newborn rats. These arteries exhibit a reduced NOS-dependent relaxation, suggesting that their basal cGMP generation is downregulated. Yet, they exhibit an enhanced relaxation response to the NO donor SNAP. Together these data strongly suggest that the pulmonary arterial vasorelaxation response to NO is dependent on the basal cGMP content.
The apparent contradictory results reported by Moreno et al. on the sildenafil-induced potentiation of the vasorelaxant effects of NO in pulmonary arteries from newborn and 2-wk-old piglets (16) is likely related to methodological differences between studies. Moreno et al. (16) studied endotheliumdenuded arteries where the endogenous cGMP generation was minimal to absent, thus likely preventing the desensitization process from occurring. Together these data indicate that the cGMP-mediated downregulation of vasorelaxation is a physiological process that might be of particular importance in the maintenance of adequate systemic vascular tone.
The sildenafil-induced downregulation of the NO-dependent pulmonary vasodilation was also documented in the present study in the chronic hypoxia-induced newborn rat model of pulmonary hypertension. In these pulmonary hypertensive animals, we have previously shown that PVR is elevated (7, 18) and PDE5 activity is increased (18) . Yet, there is animal (27) and clinical (12) evidence that the sildenafil and inhaled NO combination results in greater pulmonary vasodilation compared with the use of either agent individually. Sildenafil has been recently shown to have a positive inotropic effect on cardiomyocytes (24) , possibly explaining its additive therapeutic beneficial effect independent from its pulmonary vasodilator activity.
In summary, we documented in newborn and juvenile rat pulmonary arterial tissue a cGMP-dependent desensitization of the subsequent vasorelaxant response to PKA-and PKGdependent pharmacological agonists. This phenomenon is not unique to the pulmonary vasculature and is also present in newborn aorta-derived SMC. Further investigation of this phenomenon is warranted given the reliance on combined pulmonary vasodilatory therapeutic strategies for the PPHN syndrome.
